Literature DB >> 24346744

Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility.

Ric M Procyshyn1, Johnny Su, Dean Elbe, Angela Y Liu, William J Panenka, Jana Davidson, William G Honer, Alasdair M Barr.   

Abstract

The objective of this study was to examine the prevalence and patterns of antipsychotic use in children and adolescents at the time of admission and discharge from a tertiary care inpatient psychiatric facility. This retrospective analysis included all patients 18 years and younger, who were admitted and discharged from a child and adolescent tertiary care inpatient psychiatric facility between May 1, 2008 and December 31, 2009. Data for medications at admission were obtained using a province-wide network that links all pharmacies in British Columbia, Canada to a central set of data systems, whereas data for medications at discharge were obtained using the Department of Pharmacy's (British Columbia Children's Hospital, Vancouver, British Columbia, Canada) inpatient computer database. Apart from antipsychotics, overall drug use included antidepressants, mood stabilizers, benzodiazepines, anticholinergics, stimulants, and sleep medications. Referral and discharge diagnoses were also examined. During the study period, 335 patients were admitted and discharged from the tertiary care inpatient psychiatric facility. Significantly, more patients were prescribed with an antipsychotic at the time of discharge from hospital compared with that of the time when they were admitted to hospital (51.6% vs 30.7%; P < 0.0001). Antidepressants were most often coprescribed with an antipsychotic at admission and discharge (32.0% vs 42.2%, respectively) followed by attention-deficit/hyperactivity disorder medications (22.3% vs 24.9% at admission and discharge, respectively) and anticonvulsants (19.4% vs 19.1% at admission and discharge, respectively). Whether the significant increase in antipsychotic use seen from the time of admission to discharge is solely attributed to clinical worsening or other variables requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24346744     DOI: 10.1097/JCP.0b013e3182a607dd

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

1.  Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.

Authors:  Dean Elbe; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  J Psychiatry Neurosci       Date:  2014-05       Impact factor: 6.186

Review 2.  A Scoping Review of Medications Studied in Pediatric Polypharmacy Research.

Authors:  Alexis E Horace; Negar Golchin; Elia M Pestana Knight; Neal V Dawson; Xuan Ma; James A Feinstein; Hannah K Johnson; Lawrence Kleinman; Paul M Bakaki
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

3.  An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.

Authors:  Claire Wu; Jessica Yuen; Heidi N Boyda; Ric M Procyshyn; Cathy K Wang; Yahya I Asiri; Catherine C Y Pang; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

4.  Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis.

Authors:  Lik Hang N Lee; Ric M Procyshyn; Randall F White; Todd S Woodward; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.240

Review 5.  A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents.

Authors:  Thomas Dodsworth; David D Kim; Ric M Procyshyn; Colin J Ross; William G Honer; Alasdair M Barr
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2018-07-16       Impact factor: 3.033

Review 6.  Defining pediatric polypharmacy: A scoping review.

Authors:  Paul M Bakaki; Alexis Horace; Neal Dawson; Almut Winterstein; Jennifer Waldron; Jennifer Staley; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; Hannah Johnson; Negar Golchin; James A Feinstein; Shari D Bolen; Lawrence C Kleinman
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

7.  Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.

Authors:  Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2014-09-05       Impact factor: 4.157

Review 8.  Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.

Authors:  Lurdes Tse; Alasdair M Barr; Vanessa Scarapicchia; Fidel Vila-Rodriguez
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.